Pfizer Inc. (PFE) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for Pfizer Inc. (PFE) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow cagr for Pfizer Inc. (PFE) stock is N/A over the past 12 months. The 3 year average growth rate is -24.07% and the 5 year cagr is -3.45%. Operating cash flow CAGR measures the compound annual growth rate of the cash Pfizer Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
PFE Operating Cash Flow CAGR Chart
Pfizer Inc. (PFE)
PFE Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $12.74B | $11.71B | $-1.04B | -8.15% | -8.15% |
| 2024 | $8.70B | $12.74B | +$4.04B | +46.48% | +46.48% |
| 2023 | $29.27B | $8.70B | $-20.57B | -70.27% | -70.27% |
| 2022 | $32.58B | $29.27B | $-3.31B | -10.17% | -10.17% |
| 2021 | $14.40B | $32.58B | +$18.18B | +126.20% | +126.20% |
| 2020 | $12.59B | $14.40B | +$1.81B | +14.42% | +14.42% |
| 2019 | $15.83B | $12.59B | $-3.24B | -20.47% | -20.47% |
| 2018 | $16.47B | $15.83B | $-643.00M | -3.90% | -3.90% |
| 2017 | $15.90B | $16.47B | +$569.00M | +3.58% | +3.58% |
| 2016 | $14.51B | $15.90B | +$1.39B | +9.57% | +9.57% |
| 2015 | $16.88B | $14.51B | $-2.37B | -14.04% | -14.04% |
| 2014 | $17.77B | $16.88B | $-882.00M | -4.96% | -4.96% |
| 2013 | $17.05B | $17.77B | +$711.00M | +4.17% | +4.17% |
| 2012 | $20.24B | $17.05B | $-3.19B | -15.74% | -15.74% |
| 2011 | $11.45B | $20.24B | +$8.79B | +76.71% | +76.71% |
| 2010 | $16.59B | $11.45B | $-5.13B | -30.95% | -30.95% |
| 2009 | $18.24B | $16.59B | $-1.65B | -9.05% | -9.05% |
| 2008 | $13.35B | $18.24B | +$4.88B | +36.58% | +36.58% |
| 2007 | $17.59B | $13.35B | $-4.24B | -24.10% | -24.10% |
| 2006 | $14.73B | $17.59B | +$2.86B | +19.42% | +19.42% |
| 2005 | $16.34B | $14.73B | $-1.61B | -9.83% | -9.83% |
| 2004 | $11.74B | $16.34B | +$4.60B | +39.19% | +39.19% |
| 2003 | $10.18B | $11.74B | +$1.56B | +15.28% | +15.28% |
| 2002 | $9.26B | $10.18B | +$920.00M | +9.93% | +9.93% |
| 2001 | $6.20B | $9.26B | +$3.07B | +49.52% | +49.52% |
| 2000 | $3.06B | $6.20B | +$3.14B | +102.72% | +102.72% |
| 1999 | $2.93B | $3.06B | +$127.00M | +4.34% | +4.34% |
| 1998 | $1.63B | $2.93B | +$1.30B | +79.80% | +79.80% |
| 1997 | $2.07B | $1.63B | $-438.00M | -21.19% | -21.19% |
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla